Bayer AG

Most Recent

  • uploads///GBUs Q  performance
    Company & Industry Overviews

    Sanofi’s Organizational Restructuring: Investor Insights

    On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.

    By Sarah Collins
  • uploads///glowing _
    Company & Industry Overviews

    Verastem Stock Plunged 19.98% Yesterday

    On September 25, Verastem (VSTM) stock fell to $7.15, a ~19.98% fall from its previous close of $8.93.

    By Daniel Collins
  • uploads///XARELTO
    Company & Industry Overviews

    Opportunities and Competition for J&J’s Blockbuster Drug, Xarelto

    Xarelto is a blood thinner developed and commercialized by Johnson & Johnson’s (JNJ) subsidiary, Janssen, and Bayer (BAYZF).

    By Sarah Collins
  • uploads///Biopharmaceuticals
    Company & Industry Overviews

    Novo Nordisk’s Biopharmaceuticals Segment: An Update

    Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018.

    By Daniel Collins
  • uploads///PAH
    Company & Industry Overviews

    Johnson & Johnson’s Pulmonary Hypertension Business

    In the first quarter, Johnson & Johnson’s Pulmonary Hypertension segment reported revenues of $585.0 million.

    By Daniel Collins
  • uploads///Praluent
    Company & Industry Overviews

    How Regeneron’s Praluent and Dupixent Performed in 1Q18

    In 1Q18, Regeneron Pharmaceuticals’ (REGN) Praluent reported revenue of $60 million compared to $36 million in 1Q17.

    By Daniel Collins
  • uploads///Cabometyx
    Company & Industry Overviews

    Cabometyx Could Be Exelixis’s Long-Term Growth Driver

    In March 2018, the FDA accepted Exelixis’s (EXEL) supplemental New Drug Application (or sNDA) for Cabometyx.

    By Daniel Collins
  • uploads///BAYERS BUSINESSES
    Company & Industry Overviews

    Bayer Completes Sale of Its European Imaging Device Business

    On March 6, 2018, Innovatus Imaging completed the acquisition of Bayer’s (BAYZF) MVS (Multi Vendor Service) medical device repair business in Europe.

    By Sarah Collins
  • uploads///Womens Health
    Company & Industry Overviews

    How Merck’s Women’s Health Segment Performed in 2017

    In 4Q17, Merck’s Implanon-Nexplanon reported revenues of $183 million, which was ~14% higher on a YoY basis and a ~18% rise on a QoQ basis.

    By Daniel Collins
  • uploads///Cardiovascular
    Company & Industry Overviews

    How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017

    In 4Q17, Merck’s Zetia reported revenues of $323 million, which was ~44% lower on a year-over-year basis and a 1% rise on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Pulmonary hypertension
    Company & Industry Overviews

    How JNJ’s Hypertension Segment Performed in 4Q17

    In 2017, Uptravi generated revenues of $236.0 million.

    By Daniel Collins
  • uploads///LOE
    Company & Industry Overviews

    How Pfizer’s Peri-LOE Products Performed in 2017

    Pfizer’s (PFE) Peri-LOE products refer to those products that lost patient protection recently or are expected to lose patient protection soon.

    By Daniel Collins
  • uploads///Lyrica
    Company & Industry Overviews

    How Did Pfizer’s Viagra and Lyrica Perform in 2017?

    n fiscal 2017, Pfizer’s (PFE) Viagra reported revenues of $1.2 billion, which represented a ~23% decline on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Xtandi
    Company & Industry Overviews

    What to Expect from Pfizer’s Xtandi in 2018

    In 4Q17, Pfizer (PFE) generated revenues of $168 million from the Xtandi alliance which reflected ~21% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Sutent
    Company & Industry Overviews

    Pfizer’s Sutent Generated Higher Revenues in 4Q17

    In the US and international markets in 4Q17, Sutent generated revenues of $96 million and $180 million, respectively.

    By Daniel Collins
  • uploads///recommendations
    Company & Industry Overviews

    Analysts’ Updates after Sanofi’s Bioverativ Announcement

    In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.

    By Sarah Collins
  • uploads///Interferons
    Company & Industry Overviews

    How Biogen’s Biosimilars and Interferons Performed in 4Q17

    In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Eloctate
    Company & Industry Overviews

    How Is Bioverativ’s Eloctate Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Hemlibra
    Company & Industry Overviews

    How Is Roche’s Hemlibra Positioned for 2018?

    Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

    By Daniel Collins
  • uploads///hemophilia
    Company & Industry Overviews

    How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

    In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

    By Daniel Collins
  • uploads///Opsumit
    Company & Industry Overviews

    How JNJ’s Pulmonary Hypertension Portfolio Performed in 3Q17

    In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.

    By Daniel Collins
  • uploads///Oral care
    Company & Industry Overviews

    How JNJ’s Consumer Products Performed in 3Q17

    In 3Q17, Johnson & Johnson’s (JNJ) oral care products generated revenues of $382 million, which reflected a 3% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Regeneron’s Dupixent Approved for Atopic Dermatitis

    In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

    By Daniel Collins
  • uploads///Remodulin
    Company & Industry Overviews

    How UTHR’s Remodulin, Adcirca, and Unituxin Performed in 3Q17

    In 3Q17, United Therapeutics’ (UTHR) Remodulin reported revenues of $187.3 million, which reflected ~23% growth on a year-over-year (or YoY) basis and ~19% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Internal Medicine
    Company & Industry Overviews

    How Has Pfizer’s Internal Medicine Portfolio Performed in 2017?

    In 3Q17, Pfizer’s (PFE) Lyrica reported revenues of $1.3 billion, which is ~4% growth on a year-over-year (or YoY) basis and 2% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Tafinlar
    Company & Industry Overviews

    How 2 Key Novartis Oncology Drugs Performed in 3Q17

    In 3Q17, Novartis’s (NVS) Tafinlar-Mekinist generated revenues of $224 million, which was ~30% higher YoY (year-over-year) and 4% higher QoQ.

    By Daniel Collins
  • uploads///Hemophilia
    Company & Industry Overviews

    A Look at Novo Nordisk’s Hemophilia Franchise after 2Q17

    In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Lucentis
    Company & Industry Overviews

    How Is Novartis’s Lucentis Positioned after 1H17?

    In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Promacta Votrient jakavi
    Company & Industry Overviews

    How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17

    In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///BioMarins Developmental
    Company & Industry Overviews

    BioMarin’s Strong Pipeline Could Be a Long-Term Growth Driver

    After success in the company’s phase 1/2 trial with BMN 270, an investigational gene therapy for hemophilia A, BioMarin Pharmaceuticals (BMRN) is expected to start phase 3 trials.

    By Daniel Collins
  • uploads///Alprolix Eloctate
    Company & Industry Overviews

    How Are Bioverativ’s Key Drugs Positioned after 2Q17?

    In 2Q17, Bioverativ’s Alprolix generated revenues of ~$89.7 million, which represents ~12% growth YoY (year-over-year) and ~4% growth sequentially.

    By Daniel Collins
  • uploads///Orenitram Unituxin
    Company & Industry Overviews

    How Did United Therapeutics’ Orenitram and Unituxin Perform in 2Q17?

    In 2Q17, United Therapeutics’ (UTHR) Unituxin generated revenues of around $16 million, a 10% decline on a year-over-year (or YoY) basis and an 11% decline on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///IM
    Company & Industry Overviews

    A Post-2Q17 Look at Pfizer’s Internal Medicines

    In 2Q17, Chantix/Champix generated revenues of ~$248 million, which represents ~16% growth on a YoY basis and 4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///General Medicine Women health
    Company & Industry Overviews

    Merck’s General Medicine, Women’s Health, and Animal Health Segments

    In 2Q17, Merck’s Animal Health segment generated revenues of ~$955 million, which reflected ~6% growth on a YoY basis and ~2% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Vectibix revenues
    Company & Industry Overviews

    What We May See from Amgen’s Vectibix in 2017

    Vectibix’s revenue trends In 2Q17, Amgen’s (AMGN) Vectibix generated revenues of ~$168 million, which represented a ~5% YoY (year-over-year) rise and a ~14% QoQ (quarter-over-quarter) rise. In the US, Vectibix generated revenues of ~$62 million in 2Q17, or ~19% higher YoY. Outside the US, Vectibix reported revenues of ~$106 million, or 2% lower YoY and […]

    By Daniel Collins
  • uploads///Xgeva Revenues
    Company & Industry Overviews

    Gauging Amgen’s Xgeva Contribution in 2017

    Xgeva revenue trends In 2Q17, Amgen’s (AMGN) Xgeva generated revenues of ~$395 million, which reflected ~4% growth on a YoY (year-over-year) basis and a 2% decline on a QoQ (quarter-over-quarter) basis. In 2Q17, in the US, Xgeva generated revenues of ~$292 million, which reflected ~6% YoY growth and a ~2% QoQ decline. Outside the US, […]

    By Daniel Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Dupixent Could Substantially Drive Regeneron’s Growth

    In March 2017, the FDA approved Regeneron and Sanofi’s Dupixent injection for the treatment of adult individuals with moderate to severe atopic dermatitis.

    By Daniel Collins
  • uploads///Eylea
    Company & Industry Overviews

    Eylea Could Continue to Generate High Revenue

    Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.

    By Daniel Collins
  • uploads///Internal Medicine
    Company & Industry Overviews

    How Pfizer’s Internal Medicines Is Positioned in 2017

    In 2016, Pfizer’s (PFE) Chantix reported revenues of ~$842 million, which represents a ~25% YoY (year-over-year) rise.

    By Daniel Collins
  • uploads///Animal Health Revenues
    Company & Industry Overviews

    How Merck’s Animal Health Business Is Expected to Perform in 2017

    In 2016, Merck’s (MRK) Animal Health segment reported revenues of ~$3.5 billion, which reflected ~4% growth year-over-year.

    By Daniel Collins
  • uploads///Interferon revenues
    Company & Industry Overviews

    Biogen’s Interferon Therapies Could Witness Modest Fall in 2017

    In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Xgeva Revenue
    Company & Industry Overviews

    Xgeva Is Expected to See Robust Revenue Performance in 2017

    Amgen’s (AMGN) Xgeva was launched commercially in 2010 and is marketed primarily in the US and Europe. The drug crossed the $1 billion annual revenue mark in 2013.

    By Daniel Collins
  • uploads///US Trade in Goods with European Union
    Company & Industry Overviews

    Euro Depreciation and Its Impact on Trade with the US

    As the US economy gains strength, its impact on euro trade comes significant.

    By Mary Sadler
  • uploads///Portfolio Breakdown of the AXEAX
    Fund Managers

    Sector Composition of the Columbia European Equity Fund

    The Columbia European Equity Fund Class A (AXEAX) invests in “equity securities of European companies that are believed to offer growth potential.”

    By David Ashworth
  • uploads///Portfolio Breakdown of the AXEAX
    Fund Managers

    Sector Composition Changes in AXEAX until 1Q16

    AXEAX was invested across 69 holdings as of March 2016, seven more than a quarter ago. It was managing assets worth $515.6 million as of March.

    By David Ashworth
  • uploads///USAA International Fund Vs Peers
    Company & Industry Overviews

    How Are the USAA International Fund’s Metrics?

    From a purely NAV (net asset value) return standpoint, the USIFX did not have a notable showing in either the one-year period until February 29, 2016, or in 2015.

    By David Ashworth
  • uploads///USIFXs Top Ten Invested Geographies
    Fund Managers

    What Investors Should Know about the USAA International Fund

    The USAA International Fund (USIFX) invests at least 80% of its assets in foreign equities.

    By David Ashworth
  • Company & Industry Overviews

    ARTIX: How Is 2016 Looking so Far for the Fund?

    The Artisan International Fund – Investor Class (ARTIX) has been in existence since December 1995.

    By David Ashworth
  • uploads///Part _Agri
    Company & Industry Overviews

    Understanding DuPont’s High-Margin Agriculture Segment

    DuPont’s agriculture segment’s research and development (or R&D) expenses amounted to about 50% of its total R&D expenses in 2014.

    By Steve Ariel
  • uploads///Portfolio Break down of the AXEAX
    Macroeconomic Analysis

    How the Columbia European Equity Fund Fared until October

    As of the September portfolio of the Columbia European Equity Fund, the top ten equity holdings included Novartis, Roche Holding, and Prudential Financial.

    By David Ashworth
  • uploads///ARTIXs Top Ten Invested Geographies
    Macroeconomic Analysis

    Essentials of the Artisan International Fund (ARTIX)

    The Artisan International Fund (ARTIX) requires a minimum initial investment of $1,000. There’s no minimum or specific amount needed to add to an account.

    By David Ashworth
  • uploads///Portfolio Break down of the AXEAX
    Macroeconomic Analysis

    The Columbia European Equity Fund Class A (AXEAX): Historical Overview

    The Columbia European Equity Fund seeks capital appreciation by investing in “equity securities of European companies that…offer growth potential.”

    By David Ashworth
  • uploads///Germany
    Macroeconomic Analysis

    German Industrial Production Failed to Regain Strength in August

    The Germany industrial production index fell 1.2% in August 2015 against a revised increase of 1.2% in July.

    By Lara Sheldon
  • uploads///Euro
    Macroeconomic Analysis

    Eurozone Disappoints with Negative Inflation in September

    The Eurozone’s annual inflation is expected to fall to -0.10% in September—compared to 0.10% in August. It’s mainly attributed to the fall in energy prices.

    By Lara Sheldon
  • uploads///Graph Part
    Company & Industry Overviews

    A Key Overview of Portola

    Portola Pharmaceuticals (PTLA) is a mid-cap stock with a market capitalization of ~$3 billion. It has a weight of 0.28% in the iShares Nasdaq Biotechnology ETF (IBB).

    By Peter Neil
  • uploads///Portfolio Composition VEURX
    Macroeconomic Analysis

    Vanguard European Stock Index Fund Investor Shares (VEURX)

    As of August 2015, the Vanguard European Stock Index Fund was managing assets worth a mammoth $20.8 billion.

    By David Ashworth
  • uploads///Portfolio Composition PEUGX
    Macroeconomic Analysis

    The Putnam Europe Equity Fund: Class A (PEUGX)

    The Putnam Europe Equity Fund has been in operation since September 1990. As of August 2015, the fund was managing assets worth $370.3 million.

    By David Ashworth
  • uploads///ZTS Q
    Financials

    Livestock products lead Zoetis’ 3Q14 revenue growth

    Zoetis’ operational revenue saw growth across each of its operating segments. The increase was led by the U.S. segment, where revenue grew 7%, to $532 million, driven by sales of livestock products, mainly cattle and swine.

    By Samantha Nielson
  • uploads///ZTS industry stats
    Consumer

    Must-know trends that drive Zoetis’ growth

    Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.

    By Samantha Nielson
  • uploads///ZTS
    Financials

    Pershing Square takes 8.5% stake in Zoetis

    Pershing Square Capital Holdings added a new position in Zoetis Inc. (ZTS), which accounts for 1.52% of Pershing Square’s portfolio for the third quarter that ended in September 2014.

    By Samantha Nielson
  • Healthcare

    Third Point believes Amgen’s acquisitions should have done more

    Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.

    By Samantha Nielson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.